key: cord-0044502-72gr3hv3
authors: Sireci, Anthony N.; Patel, Jay L.; Joseph, Loren; Hiemenz, Matthew C.; Rosca, Oana C.; Caughron, Samuel K.; Thibault-Sennett, Sarah A.; Burke, Tara L.; Aisner, Dara L.
title: Molecular Pathology Economics 101: an Overview of Molecular Diagnostics Coding, Coverage and Reimbursement
date: 2020-06-03
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2020.05.008
sha: afe5cf29d3ae0a9bd2d909df1faf8a8aedb7fa75
doc_id: 44502
cord_uid: 72gr3hv3

Widespread indications for use of molecular diagnostics in various aspects of clinical medicine have driven proliferation of testing. The rapid adoption and continuous technological evolution of molecular diagnostics have often strained the development and maintenance of a functional underlying framework of coding, coverage, and reimbursement policies, thereby presenting challenges to various stakeholders including molecular professionals, payers, and patients. A multidisciplinary working group convened by the Association for Molecular Pathology Economic Affairs Committee was tasked to describe the complex landscape of molecular pathology economics and highlight opportunities for member engagement. In this manuscript, on the basis of review and synthesis of government regulations and procedures, published payer policy documents, peer-reviewed literature, and expert consensus, the Working Group navigates the ecosystem of molecular pathology economics in terms of stakeholders, coding systems and processes, coverage policy determination, and pricing mechanisms. The composition and interrelatedness of various working groups and committees are emphasized in order to highlight the functional underpinnings of the system. Molecular professionals must be conversant in the language and complex inner workings of molecular pathology economics in order to lead successful, viable laboratories and advocate effectively for policy development on their behalf. This overview is provided to be a resource to molecular professionals as they navigate the reimbursement landscape.

The economic landscape of molecular pathology testing can be overwhelming as it is an increasingly complex world of stakeholders, regulations, processes, and acronyms. This overview of Molecular Pathology economics has helped to prepare new members of the Association for Molecular Pathology (AMP) Economic Affairs Committee (EAC) for service: it is also intended to serve as an educational resource for residents, molecular pathologists, and clinical molecular geneticists, as well as laboratory directors and hospital/laboratory administrators who seek to understand the complex landscape of molecular pathology economics. In this overview, we start by defining the major stakeholders, and then take the reader through the areas of coding, coverage, and reimbursement as applied to molecular pathology diagnostics. An understanding of the complexities and challenges facing the molecular pathology community from an economic perspective is crucial for molecular diagnostic laboratories to be successful, as well as for practitioners to participate in effective advocacy and policy development.

Healthcare economics is characterized by a complex ecosystem comprising numerous stakeholders; molecular pathology is no exception. These stakeholders fall into one of three categories: healthcare providers, payers, and patients. The success of the system -as measured in terms of delivering accessible, high-quality, valueinformed care -is predicated upon buy-in and coordination between these diverse participants. Challenges arise when there is misalignment of incentives and underlying interests of the various participants; therefore, understanding and cooperation between the major stakeholders are crucial for effective problem resolution and optimal patient care.

In molecular diagnostic testing, individual providers are a broad group of specialty-trained laboratory medicine professionals including molecular pathologists Medicare beneficiaries and generally covers 80% of approved non-hospital expenses.

Medicare Parts A and B claims, including laboratory services, are processed through private companies that contract with Medicare and are called Medicare Administrative Contractors or MACs. CMS currently defines 12 MAC jurisdictions, which are groups of contiguous states. However, a single company can manage more than one MAC jurisdiction; currently four contractors control eight of the available jurisdictions ( Figure   1 ). Several changes have been implemented in the Medicare program over the past decades including expanded eligibility of some special patient categories, as well as the creation of Medicare Parts C and D. Medicare Part C, also known as Medicare proportion of medical costs. Depending on the type of molecular testing (i.e., oncology, germline, or infectious disease), coverage for and payment policies of commercial insurers may vary more or less drastically as compared to Medicare. Although inherited disease (germline) testing occurs more often in the non-Medicare population (e.g., pediatric or pregnant patients), inherited disorders are also relevant considerations in older patients (e.g., those with unexplained heart failure, patients with hereditary breast and ovarian cancer syndrome, or renal disease). In contrast, molecular testing in oncology (somatic testing) is most prominent in the Medicare population but by no means limited to that group. Although molecular testing for infectious diseases and human leukocyte antigens (HLA) is common, and many of the policies and processes detailed below apply to them, in this primer we have limited our discussion to germline and somatic testing.

Patients are the ultimate beneficiaries of access to molecular pathology services.

Patients across the spectrum of medicine can and do benefit from molecular services, however most patients are unaware of this distinct medical subspecialty. Concert Genetics reported that as of March 2019 the total number of genetic tests on the market was over 70,000 and includes single gene tests, multi-gene panels, and whole exome sequencing tests (Concert Genetics, http://www.concertgenetics.com/wpcontent/uploads/2018/04/12_ConcertGenetics_CurrentLandscapeOfGeneticTesting201 8.pdf; Accessed 11/20/2019). Utilization of molecular pathology services varies based on disease type and a number of other factors and the proportion of patients who benefit from molecular pathology services continue to grow (Personalized Medicine Coalition, http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/The_PM_Report.pdf; Accessed 10/24/2019). Advances in identifying clinically useful genetic markers, diagnostic methods, and related pharmaceutical interventions continue to increase, particularly in the oncology space, and patients are becoming more aware than ever of the value of molecular genetic testing.

Patient advocacy organizations are increasingly recognizing the role of molecular pathology and the need to engage in and respond to reimbursement policies that affect patient access to these procedures. Patient advocates, including individuals or an organization, work to improve the care and life of patients including patient rights, support, education, and care. Many patient advocacy organizations exist as diseasecentric non-profit organizations (e.g., American Cancer Society, American Diabetes Association) and work diligently to monitor both Medicare and private payer policies that may affect patient access to services, including molecular testing. For example, both supports the development and access to diagnostics to speed early diagnosis and supports updates to diagnostic reimbursement to better reflect their importance.

Patient Advocacy organizations work independently to promote coverage of molecular testing within their specific disease focus, but also work together to form coalitions to streamline engagement with the larger stakeholder community to advance healthcare policy, including reimbursement for molecular testing. A great example of these is evident in the work that LUNGevity, the largest national lung cancer-focused nonprofit, is doing. With their Take Aim Initiative they are working with a number of aligned and engaged stakeholders to ensure that patients have access to testing to help guide their treatment decision in a timely way (LUNGevity, https://lungevity.org/publicpolicy/access-to-biomarker-testing; Accessed 11/20/2019). The growing patient voice has become crucial in crafting and responding to reimbursement policy, particularly in discussions of coverage and the standards of evidence needed to justify coverage of medical services.

Several different coding systems that are used in U.S. healthcare and most relevant to molecular genetic testing are explained in brief in this section. The coding system most immediately applicable to molecular genetic testing is the AMA Current Procedure Terminology (CPT) system, which is a Level 1 Healthcare Common Procedure Coding System (HCPCS) code; others include HCPCS Level 2 codes including "G-Codes," code modifiers, and Z codes. Finally, we discuss ICD-10 codes which categorize diseases and conditions, rather than items or services.

Current Procedural Terminology (CPT), copyrighted by the AMA, is the systemized language through which providers communicate with each other, their healthcare systems and with third party payers. The CPT system was first developed as a series of 4-digit codes and published by the AMA in 1966 mainly to describe surgical procedures (1) . In 1970, the code set expanded in a second edition, which added codes for medical and therapeutic procedures and was the first 5-digit code set, the code length that is still used today.

In 1983, the HealthCare Financing Administration (HCFA; now Centers for Medicare and Medicaid Services, CMS) established the Healthcare Common Procedure

Coding System (HCPCS) and mandated use of HCPCS codes to report all services billed to Medicare. CPT was also identified by HCFA as the main procedure code set and designated as "Level 1" HCPCS codes. HCPCS coding was adopted by Medicaid in 1986, effectively making CPT the language of Medicare and Medicaid. A short time later, in 1987, the Omnibus Budget Reconciliation Act mandated the use of HCPCS codes (including Level 1 or CPT codes) for all outpatient procedures. Today, CPT is used by all federal programs and commercial payers, as a de facto standard for coding across the healthcare system, established by regulation at 45 CFR § 162.1002 (2014).

There are three main categories of CPT codes: Category I (Healthcare Common Procedural Codes), Category II (performance measurement tracking codes), and Category III (emerging technology). (Do not confuse Category I, II, and III CPT codes with the subset of molecular pathology CPT Category I codes, which are called Tier 1 and Tier 2 codes, discussed later). Category II codes are five-digit alphanumeric codes (4 digits followed by letter 'F') utilized along with the Category I codes to track nationally established performance criteria for good patient care. Category II codes facilitate quality data collection; they are not associated with any relative value and are billed with a $0.00 billable charge amount. For instance, code 3155F refers to "Cytogenetic testing performed on bone marrow at time of diagnosis or prior to initiating treatment" (American Medical Association, https://www.ama-assn.org/practice-management/category-ii-codes; Accessed 8/21/2018; Accessed 8/21/2018) (eMDs, http://www.e-mds.com/what-are-cptii-codes-and-how-are-they-used-medical-billing; Accessed 8/21/2018). Performance measures are now moving away from claims-based reporting, making these codes less and less utilized.

Category I and II codes are published yearly in the CPT manual and are effective each year on January 1. In contrast, Category III codes were developed in 2001 to provide temporary and more rapidly released codes for emerging services. They comprise 4 digits followed by the letter "T" and are released biannually. Payment for these codes is payer-dependent. There are a few cases where laboratory services are represented by Category III codes, such as code 0500T describing Human Papillomavirus (HPV) genotyping of greater than five high risk subtypes. Category III codes are typically created for a 5-year period. After 5 years, the Category III code is deleted, unless a need for its renewal is established or it is revised as a Category I code. Panel approved in 2019 and made effective January 1, 2020, the addition of a new symbol (↑↓) to indicate a PLA code that has been approved for Category I status. This symbol also indicates that while this code has achieved Category I status, the code will remain the in PLA code section of the CPT code book (American Medical Association, https://www.ama-assn.org/system/files/2019-08/may-2019-summary-panel-actions.pdf; Accessed 4/1/2020).

The requirements for PLA codes are less stringent than those for Category I/III codes: the test must be performed on human specimens and requested by the clinical laboratory or manufacturer. Each PLA code has a CPT descriptor and a subset of PLA codes are Advanced Diagnostic Laboratory Tests (ADLTs), a special category of tests subject to different policy and payment created under the Protecting Access to Medicare Act (PAMA), which was passed into law in 2014 and explained in more detail below. An ADLT is defined as a test that is offered and furnished only by a single laboratory that meets one of the following criteria 1) the test is an analysis of multiple biomarkers of DNA, RNA, or proteins when combined with a unique algorithm yields a single patientspecific result, or 2) it is a sole-source test cleared or approved by the FDA (American Medical Association, https://www.ama-assn.org/practice-management/cpt/cpt-placodes; Accessed 3/20/2020). Applications for ADLT status are a separate process from PLA code obtainment through AMA and are processed through CMS on a quarterly basis (Centers for Medicaid & Medicare Services, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Advanced-Diagnostic-Laboratory-Tests.html; Accessed 1/3/2019).

In addition to the Level 1 HCPCS CPT codes, during creation of the HCPCS codes, CMS also developed Level 2 HCPCS codes to identify and submit claims for devices, drugs, durable medical equipment and supplies. These items are not identified by CPT and are alphanumeric codes. In addition to these typical Level 2 codes, G codes (i.e., "G" plus four numerical digits) are also HCPCS Level 2 codes, created and used by CMS and they represent medical procedures. Typically, CMS creates G codes for procedures when it has requirements that are not currently served by AMA CPT Category I or III codes. When CMS defines a G code for a laboratory service, then the G code has to be used for Medicare claims for that service under the applicable circumstances. Private payers, however, may not recognize the G code and other CPT The 2020 Medicare payment for the G0452 code is $19.13 (may be higher or lower in some regions of the country) for any molecular test interpretation regardless of complexity.

Sometimes submission of a CPT or other HCPCS code to describe a rendered service does not fully explain the nature of the billed service, and additional information, such as a code modifier, is required to indicate that the procedure has been altered by a specific circumstance. This may allow preemptive explanation of a procedure code which would otherwise be denied, or to further classify the nature of a billed service providing additional information to improve accuracy. Modifiers are always two digits.

Level I Modifiers are normally referred to as CPT modifiers and consist of two numeric digits and are updated annually by the AMA. Level II Modifiers are typically referred to as HCPCS modifiers and consist of 2 alphanumeric characters and are updated annually by CMS. A comprehensive list of modifiers is available online (Noridian Healthcare Solutions, LLC, https://med.noridianmedicare.com/web/jeb/topics/modifiers; Accessed 2/7/2019). The most commonly utilized modifiers relevant to molecular pathology are discussed below.

Rates for laboratory services reimbursed on the PFS are designed to include both professional and technical components, although the value attributed to each component is not explicitly stated. In the practice of split-billing, a -TC and -26 modifier can be used, which serves to dissociate the technical component of a service from the professional component. To represent an isolated technical component bill, the CPT code is appended by the modifier *TC (a Level II modifier). Conversely, if the intent is to bill only a professional component of a service, the modifier -26 (a Level I modifier) is appended.

Another commonly used modifier, -59, is used to define distinct procedural services that are not normally reported together but are appropriate under certain circumstances. One example in molecular pathology would be the inclusion of CPT codes for fluorescence in situ hybridization (FISH) and microdissection (done in conjunction with tumor testing) for the same patient on the same date of service.

Normally, FISH and microdissection codes billed in combination would be flagged as incompatible (and therefore denied); however, because the FISH analysis and microdissection are for separate assays, the -59 modifier would be appropriate. The definition of CPT modifiers are identified in Appendix A of the CPT manual (2) . There is concern in the laboratory community that in its technical reviews, the MolDx program is redundant to regulatory oversight established by the Clinical Laboratory Improvement Act and the New York State Clinical Laboratory Evaluation Program. Additionally, MolDx may use Z-codes to assist in its claims processing of codes that would otherwise be represented by the code for unlisted molecular procedure, 81479. However, there is not agreement that 81479 appropriately captures medical service utilization for further analysis.

The International Classification of Diseases (ICD), of which ICD-10CM is the current edition, is a system of classification which describes the clinical diagnosis, condition, or scenario associated with a specific healthcare encounter. Appropriate ICD codes may accompany the diagnostic or clinical procedure code (Centers for Disease Control and Prevention, https://www.cdc.gov/nchs/icd/icd10cm.htm; Accessed 5/15/2017). The ICD is copyrighted and published by the World Health Organization. In the setting of molecular pathology testing reimbursement, ICD codes help providers support the billing of a CPT code by providing information on the clinical context for which the procedure was performed. Payers use ICD codes to determine whether the patient circumstances for the procedure meet coverage criteria.

A variety of committees and subcommittees through the AMA and other professional societies influence the coding system and those relevant to molecular pathology are described below and summarized in Figure 2 . Panel also has an Executive Committee. These five individuals comprise the chair, the co-chair, and 3 members-at-large. At least one Executive Committee member-at-large must be from a payer group.

Additional groups advise the CPT Editorial Panel on a number of matters related to molecular pathology ( Figure 2 ). The CPT Advisory Committee, a group of mainly physicians nominated from the national medical specialty societies who are seated in the AMA House of Delegates, exists to support the work of the CPT Editorial Panel.

Non-physician members drawn from the AMA Health Care Professionals Advisory Committee make up part of the Advisory Committee as well. The primary aim of the committee is to advise the CPT Editorial Panel in developing, approving and editing the CPT code set by providing expert advice on current medical practice. New codes proposals, as well as requests to modify codes are circulated to this group for comment.

The advisory committee will recommend nomenclature for procedures, provide references from the medical literature in support or denial of a specific procedure and advise on necessary revisions in the code set relevant to each member's area of expertise. The Advisory Committee is also involved in the creation and editing of AMA educational materials addressing CPT issues.

Ad hoc workgroups with subspecialty expertise advise the editorial board. There are two advisory groups that are specific to pathology and laboratory medicine which advise on matters specific to molecular codes as the need arises. The Molecular Pathology Advisory Group (MPAG), which is a standing subcommittee that advises CPT Editorial Panel on nomenclature and applicability of new and revised codes in the molecular diagnostics category, is tasked with review of all coding change applications (CCAs) that are submitted to the AMA regarding molecular pathology. The MPAG then makes its recommendations to the panel and makes them available to the Pathology Coding Caucus (PCC) to assist with their deliberations.

The PCC reviews all laboratory and pathology codes, including molecular codes that summary of a code's "lifecycle" is provided in Figure 3 .

This section will lay out the history of how CPT codes for molecular pathology procedures have evolved and then describe each group of Category I CPT codes for molecular testing, focusing on germline and somatic testing; those groups are Molecular Pathology Procedures (Tier 1 and Tier 2); Multianalyte Assays with Algorithmic Analyses (MAAAs); and Genomic Sequencing Procedures (GSPs), and the molecular pathology unlisted procedure code.

The first appearance of molecular-focused CPT codes was in 1993, with the addition of a Molecular Diagnostics section to the chemistry laboratory section, which included several separate codes for individual steps of molecular testing. From 1993 to 2002, additional CPT codes were added for other molecular services. These codes were structured differently than today's molecular codes as codes existed for each step in a molecular procedure (e.g., nucleic acid extraction, amplification, molecular probes, etc.). A laboratory performing an individual molecular assay identified each technical step within the assay and billed per the assembled codes. This practice became known as "stacking codes" because they were used in sets and multiples (e.g., DNA extraction x 1 plus probe amplification x 10). By the early 2000s, some flaws in this coding system became evident, chief among them was that payers were only able to discern that a molecular assay had been performed, but the specific analyte could not be identified. Of key importance to this newly devised coding strategy was a methodologyagnostic approach, focused on specific genes and/or conditions, which by design was quite different from the previous methodology-based approach.

Category I CPT molecular pathology procedure CPT codes are divided into two sections, or Tiers: Tier 1 and Tier 2. Tier 1 codes (81170-81355) include commonly performed analyte-specific or other well described analytic targets (e.g., CFTR screening, EGFR mutation testing, chimerism analysis). Tier 2 includes less-commonly evaluated analytes and they are grouped into nine Tier 2 codes. The nine codes in Tier 2 (81400-81408) correspond to nine levels of increasing technical complexity.

The initial distribution of analytes (typically genes) into Tier 1 and Tier 2 designations was determined based on surveys of some laboratories to determine tests that had the highest volume. Each year, some analytes are moved from Tier 2 to Tier 1 based on volume increases and the need for more specific and granular coding. assays that query a much larger fraction of the genome (e.g., exome, genome). These codes are also designed to be methodology agnostic, and it is not imperative that NGS is utilized if the panel-based descriptor of testing has been satisfied. As in other areas of coding, since the original publication of these GSP codes, new codes have been proposed and adopted, and some codes have undergone changes (e.g., the minimum gene list for hereditary colon cancer disorders (CPT 81436) increased from 7 in 2015 to 10 in 2017).

In molecular testing, the unlisted procedure code 81479 may be used until a new specific code is established (American Medical Association, 2017). This code should only be used when no existing code appropriately describes the service provided and it cannot be multiplexed. Submitting claims using an unlisted procedure code generally involves inclusion of additional documentation describing the procedure and its medical necessity. Claims without supporting documentation are generally denied. Additionally, if an appropriate existing code applies, the claim will be denied.

"Procedure-to-procedure" edits and "medically unlikely edits" were developed by There are two classes of edits. Procedure-to-procedure (PTP) edits block payment for two CPT codes on the same day of service. For example, a comprehensive code for "sequencing and duplication deletion analysis" of gene "X" would not allow additional separate billing on the same day for "sequencing" of gene X. Some of these P2P edits are hard-coded (Type 1) and some are soft-coded (Type 2), which can be overcome by a modifier (Centers for Medicare & Medicaid Services, https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/NCCI-Coding-Edits.html; Accessed 8/28/2018).

A second type of edit, medically unlikely units (MUEs), are designed to limit the number of units of a CPT code on a given date of service (DOS) for a given beneficiary.

Often this is "1", but it may be a higher multiple. Some are driven by medical logic (for example, a patient can have only "1" appendectomy). Others are driven by volume (e.g., more than "3" of a certain service is considered very unlikely and unreasonable, so an MUE edit stops payment at n=3). While many MUEs are considered absolute, some are 'soft edits' in that they can be appealed through the regular claims appeal process, while others can be overridden with the use of the -59 coding modifier. The pace of advances in molecular diagnostics is challenging to those seeking to capture its complexity while maintaining granularity of information. As the field of Molecular Pathology is undergoing rapid evolution, it is clear that the CPT codes in existence today are likely to require continued modifications. The pace and breadth of change in this discipline presents an ongoing challenge for molecular professionals, payers, and their representative organizations.

There are two formal processes Medicare uses to develop and disseminate coverage decisions and criteria for utilization of medical services: national coverage determinations (NCDs) and local coverage determinations (LCDs) (4) . The main outcome of either process is to define the clinical scenario and parameters for a medical service, which are paired with appropriate ICD-10 codes and CPT codes, to establish Medicare geography, while LCDs only apply in a specific jurisdiction in which they have been promulgated. If there is contradicting information between an NCD and an LCD, the NCD supersedes the LCD (Noridian, https://med.noridianmedicare.com/web/jea/policies/ncd; Accessed 8/28/2018).

As nearly all CMS coverage decisions for molecular tests are LCDs, understanding the LCD process is crucial for understanding molecular pathology reimbursement and coverage by CMS. Additionally, because many private insurers and LCDs may be created at the initiative of a MAC or based on a request submitted to the MAC from stakeholders within its jurisdiction. There are five main reasons that a MAC will develop an LCD: The MAC identified an item or service that is not covered under certain circumstances and wishes to establish automated review; Frequent denials are issued or anticipated; A contractor has assumed the LCD development workload of another contractor and is undertaking to make LCDs more uniform across jurisdictions; A multi-state contractor is undertaking an initiative to create uniform LCDs across its jurisdiction; An LCD is needed to assure beneficiary access to care. In response to stakeholder concern, on March 26th, the CMS Coverage and Analysis Group (CAG) announced their plans to reopen the NCD. At the end of April 2019, CMS opened a formal reconsideration of the NCD (Centers for Medicare & Medicaid Services (CMS), https://www.cms.gov/medicare-coveragedatabase/details/nca-tracking-sheet.aspx?NCAId=296; Accessed 7/19/2019). A proposed decision memo was released in late fall and a final decision released in January 2020. The final NCD released in 2020 did make changes in Section 90.2 of the National Coverage Determinations Manual to clarify that the NCD is only applicable to NGS-based tests for somatic and germline cancer. Under the NCD, CMS nationally covers tests using NGS technology for breast and ovarian cancer when the NGS test has FDA approval or clearance for use in the beneficiary's cancer and when the beneficiary meets some additional criteria such as having clinical indications for germline testing. Additionally, the local coverage section of the NCD expands MAC discretion to cover germline cancer tests using NGS technology for any cancer diagnosis, including breast and ovarian cancer (regardless of stage). MAC discretion for these tests is also dependent on additional and similar beneficiary criteria as described for national coverage. Thus, while the final NCD did not remove germline testing from the scope, as requested by many stakeholders, the final policy does allow MAC discretion for NGS-based germline testing going forward (Centers for Medicare & Medicaid Services, https://www.cms.gov/medicare-coverage-database/details/ncadecision-memo.aspx?NCAId=296&bc=AAAAAAAAABAA&; Accessed 4/8/2020).

Plans offered by commercial carriers vary considerably amongst each other and as compared to Medicare coverage policy. Individual laboratories may strategically develop preferred vendor status with a commercial carrier on a competitive basis to capture market share. In large, complex healthcare systems with complicated contracts, the needs of the contracting hospital (and insurer) are primary: individual laboratories, including the molecular pathology laboratories, are typically not a top priority for contracting considerations.

Some insurer websites list the genetic tests they will potentially cover. The mechanism for policy decisions on coverage is not usually given beyond general statements about using the best evidence available. The Blue Cross Blue Shield Association had its own rigorous and publicly available Technology Evaluation Center but has replaced it with 'Evidence Street', a web-based platform for subscribers only, which curates evidence and reviews on clinical utility submitted from a variety of sources and includes an extensive disclaimer (Blue Cross Blue Shield Association, https://www.bcbs.com/news/press-releases/blue-cross-blue-shield-associationlaunches-evidence-street-website-streamline; Accessed 7/26/2019).

Insurers will not have in-house expertise on every molecular diagnostic procedure and may utilize the services of various providers of technology assessments. (5) and the AMP-CAP Report on molecular testing for colorectal cancer (6) . This still leaves a large number of tests to evaluate. To fill this policy gap, and at the same time to streamline the process of authorizing/denying actual patient coverage requests, new organizations have arisen, called Laboratory Benefit Managers (LBMs) (GenomeWeb, https://www.genomeweb.com/molecular-diagnostics/insurers-turn-automated-prior-authorization-programs-rein-genetic-testing-use#.W4V-VbonZhE; Accessed 8/28/2018).

In recent years, health insurers have begun to utilize or build management systems that assist with various aspects of insurance policy. Major players in this space include LBMs and other evidentiary review organizations that are increasingly significant players for laboratories and their relationship with health insurers. Health plans have created, or contracted with, companies to deploy new systems to manage laboratory services; these services include medical and coverage policy development, technical assessments, claims editing, and network services. Most notably, a major focus of LBMs is administering prior authorization (or preauthorization) programs, which require that laboratories obtain approval from the health plan before it will cover the cost of a laboratory procedure. Preauthorization is increasingly becoming required for genetic and molecular oncology testing with LBMs facilitating decision-making. LBMs vary in operating style and focus and include companies such as AIM Specialty Health, Beacon Laboratory Benefit Solutions, Avalon Healthcare Solutions, Kentmere Lab Benefit Management System, and eviCore (Health Affairs, https://www.healthaffairs.org/do/10.1377/hblog20191021.563154/full/; Accessed: 3/31/2020). LBMs and their role within the healthcare system continue to grow as they expand their services. The variable degree of transparency with respect to decision making in these institutions presents a potential challenge for molecular professionals.

The level of success of LBMs in achieving purported goals such as cost savings while maintaining patient access to appropriate testing remain to be determined.

CMS pays for laboratory tests using two different fee schedules with different policy mechanisms. As noted previously, the Physician Fee Schedule (PFS) is used to pay for physician services. Making a diagnosis by taking a history and performing a physical exam is an archetypal example. For surgical pathologists the counterpart would In 2013, CMS determined that the newly developed molecular pathology codes should reside on the CLFS, not the PFS. CMS based this decision on its finding that most molecular pathology codes did not "require" the services specifically of a physician. The advantage of this arrangement across molecular pathology is the global inclusion of molecular pathology professionals across the spectrum of training, and does not exclude non-MD laboratorians from billing for these services (as would be expected if the codes were placed on the PFS). In contrast, a significant disadvantage to this approach is the general inability to recover the costs associated with complex and time consuming interpretive services (including labor time, software, databases etc.) associated with molecular testing, which can be highly variable depending on the technical details of an assay and the patient circumstance. As noted above in the section on coding, there currently exists only one option for coding of professional (physician) interpretation of molecular testing (G0452) which provides one fixed payment for any molecular pathology interpretation (currently approximately $19).

Prior to 1992, physician payments by Medicare were made on the basis of "usual, customary and reasonable charges" (UCR) as set by local claims processing contractors (also called "customary, prevailing and reasonable" (CPR)). As a result of escalating expenditures in the 1980's, the Omnibus Budget Reconciliation Act of 1989 was adopted mandating that professional service payment would be determined by the Physician Fee Schedule. The schedule is organized by codes and the relative value of CMS is not obligated to accept the RUC recommendation and can generate its own RVU evaluation. CMS publishes its final fee schedules annually. Importantly, CMS also determines the 'conversion factor': the dollar amount assigned per single RVU. In 1992 it was $31 and in 2019 it is $36. The conversion factor has historically been updated annually, in part based on the 'Medicare Economic Index' and capped by the sustainable growth rate (SGR) but has recently been changed to be determined by federal legislation.

The CLFS was authorized by the Deficit Reduction Act of 1984. It froze prices based on regional contractor fee schedules (which varied considerably) while updating them gradually based on inflation or Congressional actions. It also set a National Limitation Amount (NLA) which capped the maximum national payment, resulting in lowered payments in some jurisdictions. NLA is now essentially a historical term, because test prices will be reset every three years by national private payer rate surveys (see PAMA section below).

In 2014, payment for laboratory tests in hospital outpatient settings were folded into a single charge for the visit (the Hospital Outpatient Prospective Payment System (HOPPS)), with the exception of molecular diagnostic tests, which remain separately reimbursed using the CLFS. Note that hospital outpatient settings may include hospital outpatient clinics, emergency rooms, as well as affiliated medical clinics that are owned by a hospital and classified as outpatient centers.

Prior to 2017, new codes would receive a price from CMS using one of two processes, crosswalking or gapfilling, and except for minor inflation or other administrative adjustments, laboratory prices were not reset. Since 2017, there are complex processes that reset the whole CLFS fee schedule every 3 years, established by the Protecting Access to Medicare Act (PAMA; see below) ( Figure 4) PAMA passage and implementation has been a lengthy process and paved with road bumps, with stakeholders expressing concerns about a number of issues, including which laboratories are required to report; data collection and reporting difficulties; civil monetary penalties; and the integrity of the data used to calculate the rates. One major issue for stakeholders has been how CMS defines 'applicable laboratories' (i.e., those required to report reimbursement data). There was concern by some that the way that applicable laboratories were defined biased the outcome towards significantly lower payments than is actually seen in the overall marketplace.

Smaller laboratories and hospital referral laboratories, which often have higher reimbursement rates, were mostly left out of the original definition. AMP and others expressed concern that it would be difficult for hospital and other laboratories to accurately extract payer information from their records as many laboratories do not have the systems in place to determine the private payer payment rates for each test in )). In addition, CMS did expand the definition of applicable laboratories, effective January 1, 2019, to include laboratories that use the 14X bill type. This change will result in many more hospital outreach laboratories having to report.

The summary of PAMA data reporting in 2017 shows that 75% of tests on the CLFS had rates decreased, 10% of rates increased, and 15% did not change (Centers for Medicaid & Medicare Services, https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Downloads/CY2018-CLFS-Payment-System-Summary-Data.pdf; Accessed: 4/10/2020). While it was projected that PAMA would save over $300 million in a calendar year, CMS analysis of the first reporting period found that the impact for calendar year 2018 would be closer to $670 million. According to the Office of Inspector General's (OIG) July 2018 report, during the first round of PAMA, laboratories reported difficulty determining if they met CMS's criteria to report applicable information (U.S. Department of Health and Human Services Office of the Inspector General, https://oig.hhs.gov/oei/reports/oei-09-17-00050.pdf; Accessed: 4/10/2020). The OIG reported that at least 20 high-volume independent laboratories did not report in 2017 that likely met the majority criterion. Further, CMS reported that 37% of reporting laboratories were exempt from reporting because they did not meet the requirements of the low-expenditure threshold. The report concluded that these problems may not have had a meaningful impact on the 2018 rates, but pose a risk in future reporting periods.

Significant concern about many aspects of PAMA continue. The second data collection period occurred from January 1, 2019 to June 30, 2019 and the data collected during that time would have needed to be reported to CMS by applicable laboratories starting in January 2020. However, during 2019, there were legislative efforts to stall this reporting period to give laboratories more time to report and collect data as well as commission a study to assess how to improve PAMA implementation, the Laboratory Access for Beneficiaries (LAB) Act of 2019. In December, Congress passed the LAB Act (included in the Further Consolidated Appropriations Act, Pub. L. 116-94 (2020)) and PAMA reporting for CDLTs that are not ADLTs was delayed by one year. The LAB Act did not eliminate the statutory phase-in of rate reductions, but did reduce the maximum cut that could be applied. For 2020, the rates for CDLTs that are not ADLTs or new CLDTs may not be reduced by more than 10% of the rates for 2019. There will be a 15% reduction cap for each of 2021, 2022, and 2023 (Centers for Medicare & Medicaid Services, https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network MLN/MLNMattersArticles/Downloads/SE19006.pdf; Accessed 3/30/2020).

Additionally, in response to the 2019 Coronavirus (COVID-19) pandemic, Congress passed and the President signed into law a piece of legislation in March of 2020 to respond to the economic toll COVID-19 had taken on the United States. The Coronavirus Aid, Relief, and Economic Security (CARES) Act provided $2 trillion to stimulate the economy and respond to the COVID-19 pandemic (Coronavirus Aid, Relief, and Economic Security Act, Pub. L. No. 116-136 (2020) ). The legislation included a PAMA provision in Section 3718, which prevented scheduled reductions in Medicare payments for clinical diagnostic laboratory tests furnished to beneficiaries in 2021 and delays the upcoming laboratory data reporting period by an additional year beyond the LAB Act. Following these two pieces of legislation, the next round of PAMA reporting will begin on January 1, 2022 and will end on March 31, 2022.

The economic landscape of molecular pathology diagnostics is a complicated interplay between many stakeholders and distinct from that of other laboratory tests. Adding to the complexity is the rapid pace of adoption of novel technologies in molecular pathology requiring constant changes to the coding, coverage and reimbursement landscape. Please refer to Table 1 for a list of helpful websites to stay up to date on these programs and policies. It is the right and the responsibility of molecular professionals to be part of the conversation surrounding these changes to the system as decisions made will ultimately impact our ability to offer molecular testing and our patients' access to novel and potentially life-saving diagnostics. Once a code is created, subsequent and separate processes exist for both pricing and coverage of that code. Existing CPT codes were repriced in 2017 based on the weighted median of private payer rates submitted by applicable laboratories. If adequate data from applicable laboratories is not provided, CMS reverts pricing back to gapfill or crosswalk. Every three years, CPT codes on the clinical laboratory fee schedule (CLFS) will be revalued to align with market data from applicable laboratories as described above.

From 2010 to 2016, the number of uninsured trended lower and it was estimated that 20 million adults gained coverage via the ACA through 2016, through Medicaid expansion or through subsidized insurance

Commercial insurance carriers collectively provide health coverage for most

Health Insurance Coverage in the United States: 2017"). The plans are sold by private carriers to individuals or as a group plan through employers

A Kaiser Family Foundation survey of data for 2016 reported private insurance covered 173.9 million non-elderly adults and 42.3 million children. 56% of adults (48% of children) were covered by employer-based group insurance

6%) by non-group private insurance; 22% (39.0%) by Medicaid; 4.0% (2.5%) by 'other public', and 10.0% (5%) were uninsured (Henry J. Kaiser Family Foundation, "State Health Facts -Health Insurance Status")

Current procedural terminology; a primer

CPT 2018: Standard Edition

New thinking on clinical utility: hard lessons for molecular diagnostics

The interface of Medicare coverage decision-making and emerging molecular-based laboratory testing

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the

Tables Table 1: Molecular Pathology Economics Website Resources CODING

Proprietary Laboratory Assay (PLA) Code Set

Centers for Disease Control and Prevention's (CDC) International Classification of Diseases

Internet-Only-Manuals-IOMs-Items/CMS019033.html CMS -Medicare Coverage Database

Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files CMS -CLFS Annual Public Meeting

Payment/ClinicalLabFeeSched/Laboratory_Public_Meetings.html CMS -Advisory Panel on Clinical Diagnostic Laboratory Tests

Guidance/Guidance/FACA/AdvisoryPanelonClinicalDiagnosticLaboratoryTests.html CMS -Physician Fee Schedule Look-Up Tool

All online resources last accessed

The authors would like to acknowledge Bruce Quinn, Marc Synovec and Katherine Tynan for their review and comments on this work. Additionally, thanks to former members and current advisors to the EAC Jan Nowak and Aaron Bossler for their contributions.Disclaimer The Association for Molecular Pathology (AMP) Special Reports are developed to be of assistance to laboratory and other healthcare professionals by providing guidance and recommendations for particular areas of practice. The guidelines or reports should not be considered inclusive of all proper approaches or methods, or exclusive to others. The guidelines or reports cannot guarantee any specific outcome, nor do they establish a standard of care. The guidelines or reports are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the independent judgement of healthcare providers and each patient's individual circumstances. AMP makes no warranty, express or implied, regarding the guidelines or reports and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. AMP shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.

All committees listed here are within the American Medical Association (AMA); AMA develops and maintains its proprietary CPT 

Responsible for pricing of fee-for-service Medicare payments

Charged with promoting national correct coding methodologies and controlling improper coding. Publishes annual NCCI coding policy manual. Utilizes contractors to assist in this process

Function as gatekeepers to laboratory testing by providing preauthorization for testing on behalf of certain payers and other services such as evidence review, coverage development, and claims processing. Can exist as separate entities or created by an insurance company.

Web-based, subscriber-only curation service which assesses evidence and clinical utility of various medical procedures. Created and operated by the BlueCross BlueShield Association. 

Re-pricing every 3 years using market data